EDDING GENOR (06998) has announced that the first patient has been successfully dosed in its Phase Ib/II clinical trial for GB268, a highly differentiated innovative PD-1/CTLA-4/VEGF trispecific antibody, on August 5, 2026.

This trial targets patients with locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. The study encompasses multiple treatment arms, including monotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with antibody-drug conjugate regimens.

The primary endpoints of the study are to evaluate the safety and tolerability of GB268 combination therapies, including dose-limiting toxicities (DLTs), as well as to assess the preliminary anti-tumor activity of GB268 as a monotherapy and in combination with different treatment regimens across the relevant breast cancer populations.

The clinical protocol spans the full treatment spectrum from first-line to later-line settings, marking the first step in comprehensively expanding the application scope of GB268. The company also plans to initiate multiple combination therapy clinical studies in additional advanced solid tumor indications in the future.

Phase I monotherapy clinical data for GB268 is scheduled to be presented at the European Society for Medical Oncology (ESMO) congress in the fourth quarter of 2026.